These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34772891)

  • 1. Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review.
    Matusik E; Boidin C; Friggeri A; Richard JC; Bitker L; Roberts JA; Goutelle S
    Ther Drug Monit; 2022 Feb; 44(1):86-102. PubMed ID: 34772891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
    Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
    Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical considerations for individualizing drug dosing in critically ill adults receiving renal replacement therapy.
    Kanji S; Roger C; Taccone FS; Muller L
    Pharmacotherapy; 2023 Nov; 43(11):1194-1205. PubMed ID: 37491976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibiotic Dosing for Critically Ill Adult Patients Receiving Intermittent Hemodialysis, Prolonged Intermittent Renal Replacement Therapy, and Continuous Renal Replacement Therapy: An Update.
    Hoff BM; Maker JH; Dager WE; Heintz BH
    Ann Pharmacother; 2020 Jan; 54(1):43-55. PubMed ID: 31342772
    [No Abstract]   [Full Text] [Related]  

  • 5. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
    Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
    Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial.
    Abdulla A; Ewoldt TMJ; Hunfeld NGM; Muller AE; Rietdijk WJR; Polinder S; van Gelder T; Endeman H; Koch BCP
    BMC Infect Dis; 2020 Jan; 20(1):57. PubMed ID: 31952493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring of Antibiotics in Critically Ill Patients: Current Practice and Future Perspectives With a Focus on Clinical Outcome.
    Koch BCP; Muller AE; Hunfeld NGM; de Winter BCM; Ewoldt TMJ; Abdulla A; Endeman H
    Ther Drug Monit; 2022 Feb; 44(1):11-18. PubMed ID: 34772892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
    J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of β-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures.
    Wong G; Briscoe S; McWhinney B; Ally M; Ungerer J; Lipman J; Roberts JA
    J Antimicrob Chemother; 2018 Nov; 73(11):3087-3094. PubMed ID: 30137377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
    Abdul-Aziz MH; Sulaiman H; Mat-Nor MB; Rai V; Wong KK; Hasan MS; Abd Rahman AN; Jamal JA; Wallis SC; Lipman J; Staatz CE; Roberts JA
    Intensive Care Med; 2016 Oct; 42(10):1535-1545. PubMed ID: 26754759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Drug Monitoring of Antibiotics: Defining the Therapeutic Range.
    Abdul-Aziz MH; Brady K; Cotta MO; Roberts JA
    Ther Drug Monit; 2022 Feb; 44(1):19-31. PubMed ID: 34750338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug dosing considerations in continuous renal replacement therapy.
    Jang SM; Awdishu L
    Semin Dial; 2021 Nov; 34(6):480-488. PubMed ID: 33939855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of a Real-Time TDM-Based Expert Clinical Pharmacological Advice Program in Optimizing the Early Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Beta-Lactams among Orthotopic Liver Transplant Recipients with Documented or Suspected Gram-Negative Infections.
    Gatti M; Rinaldi M; Laici C; Siniscalchi A; Viale P; Pea F
    Antibiotics (Basel); 2023 Nov; 12(11):. PubMed ID: 37998801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?
    Jamal JA; Mueller BA; Choi GY; Lipman J; Roberts JA
    Diagn Microbiol Infect Dis; 2015 May; 82(1):92-103. PubMed ID: 25698632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial pharmacokinetics and dosing in critically ill adults receiving prolonged intermittent renal replacement therapy: A systematic review.
    Grewal A; Thabet P; Dubinsky S; Purkayastha D; Wong K; Marko R; Hiremath S; Hutton B; Kanji S
    Pharmacotherapy; 2023 Nov; 43(11):1206-1220. PubMed ID: 37596844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of a β-lactam therapeutic drug monitoring program: Experience from a large academic medical center.
    Venugopalan V; Hamza M; Santevecchi B; DeSear K; Cherabuddi K; Peloquin CA; Alshaer MH
    Am J Health Syst Pharm; 2022 Sep; 79(18):1586-1591. PubMed ID: 35704702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-lactam exposure and safety in intermittent or continuous infusion in critically ill children: an observational monocenter study.
    Debray A; Callot D; Hirt D; Bille E; Renolleau S; Chouchana L; Tréluyer JM; Oualha M; Béranger A
    Eur J Pediatr; 2023 Mar; 182(3):965-973. PubMed ID: 36422708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensuring target concentrations of antibiotics in critically ill patients through dose adjustment.
    Gorham J; Taccone FS; Hites M
    Expert Opin Drug Metab Toxicol; 2022 Mar; 18(3):177-187. PubMed ID: 35311440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
    Westermann I; Gastine S; Müller C; Rudolph W; Peters F; Bloos F; Pletz M; Hagel S
    Br J Clin Pharmacol; 2021 Nov; 87(11):4293-4303. PubMed ID: 33818823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.